Psychiatric morbidity at a Female Residential Drug Treatment Centre in Hong Kong

East Asian Archives of Psychiatry

Volumn 21, Issue 1, 2011, Pages 28-31

  Tang, Alan ^a   Cheung, Rachel Yau Kar ^a   Liang, H J ^b   Ungvari, G S ^c   Tang, Wai Kong ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF NOTRE DAME   (Australia)

Author keywords

Female; Mental disorders; Substance related disorders

Indexed keywords

COCAINE; KETAMINE; METHAMPHETAMINE;

ARTICLE; COMORBIDITY; DEMOGRAPHY; DRUG DEPENDENCE TREATMENT; FEMALE; HONG KONG; HUMAN; MOOD DISORDER; QUESTIONNAIRE; STRUCTURED INTERVIEW; SUBSTANCE ABUSE;

ADOLESCENT; ADULT; COMORBIDITY; FEMALE; HONG KONG; HUMANS; INTERVIEW, PSYCHOLOGICAL; MENTAL DISORDERS; QUESTIONNAIRES; RESIDENTIAL TREATMENT; SOCIOECONOMIC FACTORS; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 79953828854     PISSN: 20789947     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Central Registry of Drug Abuse Fifty-sixth Report. Chapter 2: Drug abuse trends for 1997-2006. Hong Kong SAR Government, Narcotics Division, Security Bureau website: http://www.nd.gov.hk/sc/report/ptf/56th/chapter2.pdf. Accessed 31 May 2010.
2. Central Registry of Drug Abuse and Drug Statistics. Newly / previously reported drug abusers by age group by common type of drugs abused (Table 3). Hong Kong SAR Government, Narcotics Division, Security Bureau website: http://www.nd.gov.hk/statistics-list/doc/sc/t3.pdf. Accessed 31 May 2010.
3. Compton WM, Thomas YF, Stinson FS, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry 2007;64:566-76. (Pubitemid 46718289)
4. Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 2001;25:455-67. (Pubitemid 32830950)
5. Schuckit MA. Comorbidity between substance use disorders and psychiatric conditions. Addiction 2006; 101 Suppl 1:S76-88.
6. Crome I, Bloor R. Substance misuse and psychiatric comorbidity in adolescents. Curr Opin Psychiatry 2005;18:435-9. (Pubitemid 40834967)
7. Chan YF, Godley MD, Godley SH, Dennis ML. Utilization of mental health services among adolescents in community-based substance abuse outpatient clinics. J Behav Health Serv Res 2009;36:35-51.
8. Chan YF. Dennis ML. Funk RR. Prevalence and comorbidity of major internalizing and externalizing problems among adolescents and adults presenting to substance abuse treatment. J Subst Abuse Treat 2008;34:14-24. (Pubitemid 350216349)
9. Shoptaw S, Peck J, Reback CJ, Rotheram-Fuller E. Psychiatric and substance dependence comorbidities, sexually transmitted diseases, and risk behaviors among methamphetamine-dependent gay and bisexual men seeking outpatient drug abuse treatment. J Psychoactive Drugs 2003;35 (Suppl):S161-8.
10. Kessler RC, Nelson CB, McGonagle KA, Edlund MJ, Frank RG, Leaf PJ. The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization. Am J Orthopsychiatry 1996;66:17-31. (Pubitemid 26031236)
11. Lee S, Tsang A, Chui H, Kwok K, Cheung E. A community epidemiological survey of generalized anxiety disorder in Hong Kong. Community Ment Health J 2007;43:305-19. (Pubitemid 47038084)
12. Chen RY, Lee AM, Chan RC, Chen EY, Tang SW. Study on the cognitive impairment and other harmful effects caused by ketamine abuse. Hong Kong SAR Government, Narcotics Division, Security Bureau website: http://www.nd.gov.hk/ pdf/ Study%20on%20the%20Cognitive%20 Impairment%20 and%20Other%20 Harmful%20Effects%20Caused%20by%20Ketamine%20Abuse.pdf. Accessed 31 Jan 2011.
13. Buckley TC, Parker JD, Heggie J. A psychometric evaluation of the BDI-II in treatment-seeking substance abusers. J Subst Abuse Treatment 2001;20:197-204. (Pubitemid 32552040)
14. Hepner KA, Hunter SB, Edelen MO, Zhou AJ, Watkins K. A comparison of two depressive symptomatology measures in residential substance abuse treatment clients. J Subst Abuse Treat 2009;37:318-25.
15. Compton WM 3rd, Cottler LB, Jacobs JL, Ben-Abdallah A, Spitznagel EL. The role of psychiatric disorders in predicting drug dependence treatment outcomes. Am J Psychiatry 2003;60:890-5. (Pubitemid 41079573)
16. Subramaniam GA, Stitzer MA, Clemmey P, Kolodner K, Fishman MJ. Baseline depressive symptoms predict poor substance use outcome following adolescent residential treatment. J Am Acad Child Adolesc Psychiatry 2007;46:1062-9. (Pubitemid 47220688)
17. Moos RH, Finney JW, Moos BS. Inpatient substance abuse care and the outcome of subsequent community residential and outpatient care. Addiction 2000,95:833-46. (Pubitemid 30418975)
18. CRDA and Drug Statistics. Selected Drug Abuse Statistics, Newly/previously reported drug abusers by sex by common type of drugs abused (T12). Hong Kong SAR Government, Narcotics Division, Security Bureau website: http://www.nd.gov.hk/statistics-list/doc/en/t12.pdf. Accessed 31 May 2010.
19. CRDA and Drug Statistics. Selected Drug Abuse Statistics, Reported drug abusers by sex by age of first abuse (T14). Hong Kong SAR Government, Narcotics Division, Security Bureau website: http://www.nd.gov.hk/statistics-list/doc/sc/ t14.pdf. Accessed 31 May 2010.
20. Greenfield SF, Brooks AJ, Gordon SM, Green CA, Kropp F, McHugh RK, et al. Substance abuse treatment entry, retention, and outcome in women: a review of the literature. Drug Alcohol Depend 2007;86:1-21.
21. Laidler KJ, Hodson D, Day J, Loh C. A study on the initiation, continuation and impact of drug use among females. Hong Kong SAR Government, Narcotics Division, Security Bureau website: http://www.nd.gov.hk/pdf/ Initiation%20Continuation%20and%20Impact%20of%20Drug%20Use%20Among%20Females. pdf. Accessed 31 May 2010.
22. So E, Kam I, Leung CM, Chung D, Liu Z, Fong S. The Chinese-bilingual SCID-I/P Project: stage 1 -reliability for mood disorders and schizophrenia. Hong Kong J Psychiatry 2003;13:7-18.
23. So E, Kam I, Leung CM, Pang A, Lam L. The Chinese-bilingual SCID-I/P Project: stage 2 -reliability for anxiety disorders, adjustment disorders, and 'no diagnosis'. Hong Kong J Psychiatry 2003;13:19-25.
24. CRDA and Drug statistics. Reported drug abusers by age group by sex by age of first abuse (T10). Hong Kong SAR Government, Narcotics Division website: http://www.nd.gov.hk/statistics-list/doc/sc/t10.pdf. Accessed 31 May 2010.
25. Central Registry of Drug Abuse Fifty-seventh Report. Hong Kong SAR Government, Narcotics Division website: http://www.nd.gov.hk/en/crda-report.htm. Accessed 31 May 2010.
26. Central Registry of Drug Abuse Fifty-eight Report, chapter 2: Drug Abuse Trends for 1999-2008. Hong Kong SAR Government, Narcotics Division, Security Bureau website: http://www.nd.gov.hk/pdf/report/58th/chapter2.pdf. Accessed 31 May 2010.
27. Phelps LE, Brutsche N, Moral JR, Luckenbaugh DA, Manji HK, Zarate CA Jr. Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry 2008;65:181-4.
28. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006;63:856-64. (Pubitemid 44188478)
29. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000;47:351-4. (Pubitemid 30109248)
30. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994;51:199-214.
31. Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melson AK, Hershey T, et al. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 1999;20:106-18. (Pubitemid 29010370)
32. Lahti AC, Koffel B, LaPorte D, Tamminga CA. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995;13:9-19.